Is the diagnosis of somatic‑symptom disorder and the current medication regimen (milnacipran 50 mg daily, clonazepam 0.125 mg, lemborexant 5 mg, and baclofen 20 mg extended‑release in the morning) appropriate for my chronic upper‑ and mid‑back pain, full‑body stiffness, unrefreshing sleep, and daytime fatigue?

Reassessing Your Diagnosis and Treatment Plan

Your symptoms—chronic upper and mid‑back pain, full‑body stiffness, unrefreshing sleep, and daytime fatigue—are more consistent with fibromyalgia than with somatic symptom disorder, and your current medication regimen requires optimization to align with evidence‑based guidelines for fibromyalgia management. 1

Reconsidering the Diagnosis

Your constellation of symptoms strongly suggests fibromyalgia rather than somatic symptom disorder (SSD):

• Fibromyalgia is characterized by widespread chronic pain (≥3 months), multiple tender points, full‑body stiffness, unrefreshing sleep, and daytime fatigue—all of which you describe 2.
• Somatic symptom disorder requires that the person places excessive emphasis on physical symptoms causing disproportionate thoughts, feelings, and behaviors, with symptoms being an "overstated reaction" 3. Your description does not indicate this psychological overreaction pattern.
• The distinction matters because fibromyalgia has specific evidence‑based pharmacologic treatments (SNRIs like milnacipran, pregabalin, duloxetine) 2, 1, whereas SSD treatment focuses primarily on cognitive‑behavioral therapy and treating comorbid anxiety/depression 4, 3.

Common pitfall: Chronic pain patients are frequently misdiagnosed with SSD when their symptoms actually meet criteria for fibromyalgia or other functional pain syndromes 2, 1. Request clarification from your psychiatrist about whether formal fibromyalgia diagnostic criteria (widespread pain index and symptom severity scale) were assessed.

Evaluating Your Current Medications

Milnacipran 50 mg Daily

• This dose is suboptimal. The FDA‑approved target dose for fibromyalgia is 100 mg/day (50 mg twice daily), with possible escalation to 200 mg/day based on response 5.
• Milnacipran (an SNRI) has strong evidence for fibromyalgia: it achieved statistically significant improvements in pain, global well‑being, and fatigue with effect sizes equal to tricyclic antidepressants 6. The number needed to treat (NNT) for moderate benefit is approximately 8 2.
• Recommendation: Increase to 100 mg/day (50 mg twice daily) after appropriate titration 5. If pain remains uncontrolled after 8–12 weeks at 100 mg/day, consider adding pregabalin 150–450 mg daily 1.

Clonazepam 0.125 mg

• This medication is not recommended for chronic pain or fibromyalgia. Benzodiazepines have minimal analgesic data (one case report for neuralgic pain) and are only "rarely considered" when neuropathic pain is refractory to other therapies 7.
• The American Society of Anesthesiologists states that consultants and members disagree or are equivocal about using benzodiazepines for chronic pain 8.
• The 2022 VA/DoD guideline for chronic multisymptom illness (which includes fibromyalgia) does not support benzodiazepine use 9.
• Risks: Abuse potential, lack of long‑term benefit, cognitive impairment, and falls—especially problematic if you develop comorbid dementia over time 10, 1.
• Recommendation: Taper and discontinue clonazepam 1. If anxiety or sleep issues persist after discontinuation, address them with cognitive‑behavioral therapy or consider low‑dose mirtazapine (7.5–30 mg at bedtime) 11, 9.

Lemborexant 5 mg

• This is appropriate for insomnia. Lemborexant (a dual orexin receptor antagonist) significantly improves sleep onset latency, wake after sleep onset, and sleep efficiency compared to placebo 12, 13, 14.
• It is well‑tolerated in older adults (≥65 years) and in patients taking medications for depression/anxiety, with mild somnolence being the most common side effect 13, 14.
• Recommendation: Continue lemborexant 5 mg for unrefreshing sleep 12, 14. Monitor for excessive daytime somnolence; if this occurs, the dose is already at the lower effective level, so consider non‑pharmacologic sleep interventions (cognitive‑behavioral therapy for insomnia, sleep hygiene) 11, 9.

Baclofen 20 mg ER (Morning Only)

• This is not evidence‑based for chronic back pain or fibromyalgia. Baclofen (a GABA‑B agonist) is FDA‑approved for spasticity, not chronic musculoskeletal pain 7.
• Limited data exist: one controlled trial showed efficacy in trigeminal neuralgia, and one older study suggested baclofen may help spinal spasticity more than cerebral spasticity 7, 15.
• Guidelines state that "so‑called muscle relaxants" (including baclofen) have no evidence of efficacy in chronic pain and are not favored due to adverse effects 7, 1.
• Recommendation: Taper and discontinue baclofen 1. If muscle stiffness persists, address it with physical therapy, aquatherapy, and aerobic exercise—the strongest evidence‑based non‑pharmacologic treatments for fibromyalgia 9, 1.

Optimized Treatment Algorithm

Step 1: Medication Optimization (Weeks 0–12)

1. Increase milnacipran from 50 mg once daily to 100 mg/day (50 mg twice daily) using the FDA titration schedule 5:

   • Days 1–3: 25 mg/day (12.5 mg twice daily)
   • Days 4–7: 50 mg/day (25 mg twice daily)
   • After Day 7: 100 mg/day (50 mg twice daily)

2. Taper and discontinue clonazepam over 2–4 weeks to avoid withdrawal symptoms 1.

3. Taper and discontinue baclofen over 2–4 weeks 1.

4. Continue lemborexant 5 mg at bedtime 12, 14.

Step 2: Add Non‑Pharmacologic Interventions (Weeks 0–12)

• Aerobic exercise is the strongest evidence‑based treatment for fibromyalgia (strong evidence) 1. Start with low‑impact activities (walking, swimming, aquatherapy) and gradually increase intensity.
• Cognitive‑behavioral therapy (CBT) improves pain intensity and functional outcomes in fibromyalgia and chronic multisymptom illness 9, 1.
• Yoga or tai chi can reduce low‑back pain and fibromyalgia symptoms 9, 1.
• Physical therapy combining aerobic and strengthening exercises 1.

Step 3: Reassess at 8–12 Weeks

• Measure pain intensity (0–10 numeric rating scale) and functional status 1.
• If pain remains uncontrolled on milnacipran 100 mg/day:
  • Add pregabalin 150–450 mg daily (start 75 mg twice daily, titrate weekly) 1. Pregabalin has moderate evidence for fibromyalgia pain reduction (NNT 6–9) 2, 9.
  • Alternatively, consider switching to duloxetine 60 mg once daily (FDA‑approved for fibromyalgia, NNT similar to milnacipran) 1.

Step 4: Referral if No Improvement (Week 12)

• If no clinically meaningful improvement after 8–12 weeks of optimized pharmacologic and non‑pharmacologic therapy, refer to a pain specialist or multidisciplinary pain center 1.

Key Pitfalls to Avoid

• Do not continue clonazepam or baclofen long‑term for chronic pain—they lack efficacy and carry significant risks 7, 8, 1.
• Do not initiate opioids before adequate trials of SNRIs, pregabalin, and non‑pharmacologic therapies 9, 1. Opioids provide minimal long‑term benefit for fibromyalgia and carry substantial harm 2, 9.
• Do not use NSAIDs for fibromyalgia—they are ineffective for this condition 9, 1.
• Do not underdose milnacipran—50 mg/day is below the therapeutic target of 100 mg/day 5, 6.

Monitoring and Follow‑Up

• Reassess pain and functional status every 4–6 weeks 1.
• Monitor for suicidality, especially during the first weeks of milnacipran dose escalation (black‑box warning for SNRIs) 5.
• Screen for and treat comorbid depression and anxiety, as these exacerbate fibromyalgia symptoms 1.
• If discontinuing milnacipran in the future, taper gradually to avoid withdrawal symptoms 5.